{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:47:50Z","timestamp":1782197270114,"version":"3.54.5"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011501","name":"Qinghai Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Yersinia pestis<\/jats:italic>\n                      , a category A infectious organism, is known to cause bubonic, septicemic, and pneumonic plague. With the emergence of streptomycin-resistant strains, there is an urgent need for new therapeutic strategies that can protect populations from\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      infection. The main strategy for developing vaccines and therapeutic antibodies involves F1 antigen. Previous research has demonstrated that both human and murine monoclonal antibodies(mAbs) confer protective effects against\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      infection. While, no relevant studies were identified on mAbs against drug-resistance\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here, we constructed an antibody library from\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      vaccine strain EV76-immunized mice by phage display. The mAbs were baited by recombinant F1 antigen, and the biological functions of the obtained mAbs were assessed and evaluated in plague-challenged mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For the\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      strain 141 group, both Fm3 and Fm25 provided 100% protection at a dose of 100 \u00b5g. At 20 \u00b5g, only Fm3 conferred partial protection, with a survival rate of 25%, whereas all mice in the 4 \u00b5g treatment groups succumbed to infection within approximately 10 days. Against the drug-resistant\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      strain S19960127, Fm25 at 100 \u00b5g resulted in complete survival, whereas Fm3 at the same dose conferred 75% protection. Neither mAbs showed protective efficacy at 20 \u00b5g or 4 \u00b5g, and all animals dying within approximately 10 days post-infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These findings indicated that mAbs Fm3 and Fm25 confer protection against virulent and drug-resistant strains of\n                      <jats:italic>Y. pestis<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1835695","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:00Z","timestamp":1782195120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenxuan","family":"Peng","sequence":"first","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]},{"name":"NHC Key Laboratory of Plague Prevention and Control, Qinghai Institute for Endemic Disease Prevention and Control","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailian","family":"Wu","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]},{"name":"NHC Key Laboratory of Plague Prevention and Control, Qinghai Institute for Endemic Disease Prevention and Control","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Prevention and Control, Department of Vaccine Clinical Evaluation","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Prevention and Control, Department of Vaccine Clinical Evaluation","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Plague Prevention and Control, Qinghai Institute for Endemic Disease Prevention and Control","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Xin","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiye","family":"Ying","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Ma","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Center for Disease Prevention and Control, Department of Vaccine Clinical Evaluation","place":["Nanjing, Jiangsu, China"]},{"name":"National Vaccine Innovation Platform, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]},{"name":"NHC Key Laboratory of Plague Prevention and Control, Qinghai Institute for Endemic Disease Prevention and Control","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Qinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province","place":["Xining, Qinghai, China"]},{"name":"NHC Key Laboratory of Plague Prevention and Control, Qinghai Institute for Endemic Disease Prevention and Control","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt3880","article-title":"Attenuation of virulence in Yersinia pestis across three plague pandemics","volume":"388","author":"Sidhu","year":"2025","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10050562","article-title":"Obtaining specific sequence tags for Yersinia pestis and visually detecting them using the CRISPR-Cas12a system","volume":"10","author":"Chen","year":"2021","journal-title":"Pathogens"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2467778","article-title":"Molecular turn in Yersinia pestis pathogenesis: implications of the gppA frameshift for bacterial survival in human macrophage","volume":"14","author":"Chen","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00044-19","article-title":"Yersinia pestis: the natural history of plague","volume":"34","author":"Barbieri","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/cid\/ciz1226","article-title":"Antimicrobial treatment of human plague: a systematic review of the literature on individual cases, 1937-2019","volume":"70","author":"Nelson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3201\/eid3002.230759","article-title":"Multiple introductions of Yersinia pestis during urban pneumonic plague epidemic, Madagascar, 2017","volume":"30","author":"Andrianaivoarimanana","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012252","article-title":"Review of genotyping methods for Yersinia pestis in Madagascar","volume":"18","author":"Randriantseheno","year":"2024","journal-title":"PloS NeglTrop Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.24171\/j.phrp.2021.0288","article-title":"Yersinia pestis antibiotic resistance: a systematic review","volume":"13","author":"Lei","year":"2022","journal-title":"Osong Public Health Res Perspect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1590\/s0037-86822011005000008","article-title":"Infec\u00e7\u00e3o por Yersinia pestis, no Estado da Bahia: controle efetivo ou sil\u00eancio epidemiol\u00f3gico? [Yersinia pestis infection in the State of Bahia: effective control or epidemiological silence","volume":"44","author":"Saavedra","year":"2011","journal-title":"Rev Soc Bras Med Trop"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2018.04.001","article-title":"A historical evaluation of Chinese tongue diagnosis in the treatment of septicemic plague in the pre-antibiotic era, and as a new direction for revolutionary clinical research applications","volume":"16","author":"Solos","year":"2018","journal-title":"J Integr Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1107\/S2053230X19011154","article-title":"Crystal structure of UDP-glucose pyrophosphorylase from Yersinia pestis, a potential therapeutic target against plague","volume":"75","author":"Gibbs","year":"2019","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2019.06.007","article-title":"Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics","volume":"21","author":"Demeure","year":"2019","journal-title":"Microbes Infect"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.micpath.2015.07.012","article-title":"MAP of F1 and V antigens from Yersinia pestis astride innate and adaptive immune response","volume":"87","author":"Rai","year":"2015","journal-title":"Microb Pathog"},{"key":"B14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/978-1-4939-3387-7_28","article-title":"Highly effective soluble and bacteriophage T4 nanoparticle plague vaccines against Yersinia pestis","volume":"1403","author":"Tao","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B15","article-title":"Primary research on determination of clinical efficacy for plague component vaccine with animal rule (in Chinese)","volume":"44","author":"Jiao","year":"2016","journal-title":"Prog Microbiol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13010066","article-title":"Live plague vaccine development: past, present, and future","volume":"13","author":"Anisimov","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-019-0065-0","article-title":"Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics","volume":"20","author":"Demeure","year":"2019","journal-title":"Genes Immun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2216085","article-title":"Functional assays to screen and select monoclonal antibodies that target Yersinia pestis","volume":"19","author":"Biryukov","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B19","article-title":"Yersinia pestis IS1541 transposition provides for escape from plague immunity","volume-title":"Infect Immun","author":"Cornelius","year":""},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.059","article-title":"T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague","volume":"29","author":"Levy","year":"2011","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01497-24","article-title":"Assessing the threat of Yersinia pestis harboring a multi-resistant IncC plasmid and the efficacy of an antibiotic targeting LpxC","volume":"69","author":"Lemaitre","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01519-17","article-title":"Plague: recognition, treatment, and prevention","volume":"56","author":"Yang","year":"2017","journal-title":"J Clin Microbiol"},{"key":"B23","volume-title":"Manual for plague surveillance, diagnosis, prevention and control","year":"2024"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7003a1","article-title":"Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response","volume":"70","author":"Nelson","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9051055","article-title":"Evaluation of the European Committee on Antimicrobial Susceptibility Testing Guidelines for Rapid Antimicrobial Susceptibility Testing of Bacillus anthracis-, Yersinia pestis- and Francisella tularensis-positive blood cultures","volume":"9","author":"Shifman","year":"2021","journal-title":"Microorganisms"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn331340-20240325-00061","article-title":"Diagnosis and treatment plan for plague (2023 edition)","volume":"51","year":"2024","journal-title":"Int J Epidemiol Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000309","article-title":"Multiple antimicrobial resistance in plague: an emerging public health risk","volume":"2","author":"Welch","year":"2007","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00306-06","article-title":"Resistance of Yersinia pestis to antimicrobial agents","volume":"50","author":"Galimand","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05043-11","article-title":"Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia","volume":"56","author":"Urich","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04548-14","article-title":"In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods","volume":"59","author":"Heine","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biom11050724","article-title":"Antibiotic therapy of plague: a review","volume":"11","author":"Sebbane","year":"2021","journal-title":"Biomolecules"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107354","article-title":"Neutralizing chimeric anti-F1 monoclonal antibody against Yersinia pestis infection","volume":"64","author":"Wang","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01054-24","article-title":"Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection","volume":"12","author":"Zhang","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00473","article-title":"Construction of a live-attenuated vaccine strain of Yersinia pestis EV76-B-SHUDpla and evaluation of its protection efficacy in a mouse model by aerosolized intratracheal inoculation","volume":"10","author":"Feng","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00111","article-title":"Human macrophages clear the biovar Q20 Microtus strain of Yersinia pestis more efficiently than murine macrophages","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.078","article-title":"Comparison of mouse, Guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270","volume":"28","author":"Qi","year":"2010","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009324","article-title":"A novel mechanism of streptomycin resistance in Yersinia pestis: mutation in the rpsL gene","volume":"15","author":"Dai","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"B40","article-title":"Expression and immunogenicity study on the recombinant F1 of Yersinia pestis in E. coli (in Chinese)","volume":"33","author":"Wang","year":"2005","journal-title":"Prog Microbiol Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052503","article-title":"Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague","volume":"7","author":"Lema\u00eetre","year":"2012","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1230","article-title":"Treatment of human plague: a systematic review of published aggregate data on antimicrobial efficacy, 1939-2019","volume":"70","author":"Godfred-Cato","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/cid\/ciab606","article-title":"Transmission of antimicrobial resistant Yersinia pestis during a pneumonic plague outbreak","volume":"74","author":"Andrianaivoarimanana","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.09.015","article-title":"Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat","volume":"51","author":"Cabanel","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9061278","article-title":"Reporter-phage-based detection and antibiotic susceptibility testing of Yersinia pestis for a rapid plague outbreak response","volume":"9","author":"Moses","year":"2021","journal-title":"Microorganisms"},{"key":"B46","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.1038\/s41598-019-49700-1","article-title":"Rapid detection of genetic engineering, structural variation, and antimicrobial resistance markers in bacterial biothreat pathogens by nanopore sequencing","volume":"9","author":"Gargis","year":"2019","journal-title":"Sci Rep"},{"key":"B47","article-title":"Clinical application and research progress of plague vaccine (in Chinese)","volume":"34","author":"Wei","year":"2021","journal-title":"China J Biol Prod"},{"key":"B48","article-title":"Passive protection level of plague vaccine phase IIa clinical serum in mice and its correlation analysis with antibody titers (in Chinese)","volume":"45","author":"Jiao","year":"2017","journal-title":"Adv Microbiol Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2014.05.010","article-title":"From the discovery of monoclonal antibodies to their therapeutic application: an historical reappraisal","volume":"161","author":"Ribatti","year":"2014","journal-title":"Immunol Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.11.008","article-title":"Antibody-based biologics and their promise to combat Staphylococcus aureus infections","volume":"37","author":"Sause","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2078160","article-title":"Therapeutic monoclonal antibodies for COVID-19 management: an update","volume":"22","author":"Chavda","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501286","article-title":"Novel bivalent mRNA-LNP vaccine for highly effective protection against pneumonic plague","volume":"12","author":"Elia","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1227","article-title":"Antimicrobial treatment patterns and illness outcome among United States patients with plague, 1942-2018","volume":"70","author":"Kugeler","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.10.108","article-title":"Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity","volume":"538","author":"Carrillo","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1997.56.471","article-title":"Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis","volume":"56","author":"Anderson","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177012","article-title":"Identification and characterization of a neutralizing monoclonal antibody that provides complete protection against Yersinia pestis","volume":"12","author":"Liu","year":"2017","journal-title":"PloS One"},{"key":"B58","first-page":"7","article-title":"The passive immuno-protection in mice by using of MAbs against Yersinia pestis F1 antigen","volume":"46","author":"Wu","year":"2018","journal-title":"Prog Microbiol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.11.4476-4482.1997","article-title":"Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization","volume":"65","author":"Hill","year":"1997","journal-title":"Infect Immun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.2234-2238.2003","article-title":"Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis","volume":"71","author":"Hill","year":"2003","journal-title":"Infect Immun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013047","article-title":"Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model","volume":"5","author":"Xiao","year":"2010","journal-title":"PloS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/ITT.S267077","article-title":"Development of anti-Yersinia pestis human antibodies with features required for diagnostic and therapeutic applications","volume":"9","author":"Lillo","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.2002.0498","article-title":"Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis","volume":"32","author":"Weeks","year":"2002","journal-title":"Microb Pathog"},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bios.2014.09.090","article-title":"Kinetic epitope mapping of monoclonal antibodies raised against the Yersinia pestis virulence factor LcrV","volume":"65","author":"Read","year":"2015","journal-title":"Biosens Bioelectron"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.5.3068-3070.2006","article-title":"Administration of antibody to the lung protects mice against pneumonic plague","volume":"74","author":"Hill","year":"2006","journal-title":"Infect Immun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00856-08","article-title":"Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge","volume":"77","author":"Sofer-Podesta","year":"2009","journal-title":"Infect Immun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.021","article-title":"Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity","volume":"25","author":"Eyles","year":"2007","journal-title":"Vaccine"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2004.08.002","article-title":"Molecular detection of Yersinia pestis isolates of Indian origin by using Pla specific monoclonal antibodies","volume":"28","author":"Mahesh","year":"2005","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1006\/mcpr.2002.0420","article-title":"Monoclonal antibodies against Yersinia pestis lipopolysaccharide detect bacteria cultured at 28 degrees C or 37 degrees C","volume":"16","author":"Prior","year":"2002","journal-title":"Mol Cell Probes"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.2008.0032","article-title":"Production and characterization of monoclonal antibodies against YopM effector protein of Yersinia pestis","volume":"28","author":"Khushiramani","year":"2009","journal-title":"Hybridoma (Larchmt)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-49-3-261","article-title":"Development, characterisation and diagnostic application of monoclonal antibodies against Yersinia pestis fibrinolysin and coagulase","volume":"49","author":"Feodorova","year":"2000","journal-title":"J Med Microbiol"},{"key":"B72","article-title":"Preparation of monoclonal antibody to V antigen from Yersinia pestis","volume":"12","author":"Sato","year":"1991","journal-title":"Contrib Microbiol Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835695\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:03Z","timestamp":1782195123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835695\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2026.1835695"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1835695","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1835695"}}